RRM2 and cancer: We performed a pan-cancer analysis of the genetic alteration status of RRM2 and observed that maximum alteration (> 4%) appeared in patients with endometrial carcinoma (Figure 2C); patients with primary type of melanoma showed an alteration frequency of ~3%.